Abnormal expression of Smurf2 during the process of rat liver fibrosis
Yu CAI
Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Search for more papers by this authorXi Zhong SHEN
Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Search for more papers by this authorChao Hui ZHOU
Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Search for more papers by this authorJi Yao WANG
Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Search for more papers by this authorYu CAI
Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Search for more papers by this authorXi Zhong SHEN
Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Search for more papers by this authorChao Hui ZHOU
Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Search for more papers by this authorJi Yao WANG
Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Search for more papers by this authorAbstract
OBJECTIVE: Liver fibrosis is a prelude of liver cirrhosis. Currently the molecular mechanism of liver fibrosis is not clear. The purpose of this study is to screen the abnormally expressed genes of liver fibrosis and to illustrate the changes of Smurf2 expression in the process of liver fibrosis.
METHODS: A liver fibrosis model was established in rats by injection of tetrachlormethane (CCl4). A cDNA microarray analysis was performed on the liver at mid-stage of fibrosis. Thereafter, a semi-quantitative RT-PCR, Western blot analysis and immunohistochemistry test were performed for determining Smurf2, Smad2 and SnoN at week 1, 2, 4 and 8 of establishing the liver fibrosis model.
RESULTS: Smurf2, FGG, PTAFR, CYP2D6, among others, increased in the fibrosis liver and a semi-quantitative RT-PCR confirmed the reliability of the cDNA microarray analysis. Smurf2 in the liver fibrosis model group was at the same level as that of control group at week 1, but decreased at week 2 and 8 and increased at the week 4. Smad2 increased at week 2 and 8 but increased at week 4. However, Smad2 mRNA increased to the same level at week 4 as that at week 2 and 8. The decrease of Smad2 at week 4 may be due to the enhancement of ubiquitination and proteolytic degradation of Smad2 by the increase of Smurf2. SnoN decreased at week 4 and 8 because of the ubiquitination and degradation caused by Smurf2. The decrease of SnoN may explain the progress of liver fibrosis in spite of the decrease of Smad2 at week 4.
CONCLUSION: This study screened the abnormally expressed genes of liver fibrosis and illustrated the changes of Smurf2, Smad2 and SnoN during the process of liver fibrosis.
REFERENCES
- 1 Eickelberg O. Endless healing: TGF-β, Smads, and fibrosis. FEBS Lett 2001; 506: 11–4.
- 2 Wells RG, Fibrogenesis V. TGF-β signaling pathways. Am J Physiol Gastrointest Liver Physiol 2000; 279: G845–50.
- 3 Bauer M, Schuppan D. TGFβ1 in liver fibrosis: time to change paradigms? FEBS Lett 2001; 502: 1–3.
- 4 Wrana JL. Transforming growth factor-β signaling and cirrhosis. Hepatology 1999; 29: 1909–10.
- 5 Bissell DM, Roulot D, George J. Transforming growth factor β and the liver. Hepatology 2001; 34: 859–67.
- 6 Bissell DM, Wang SS, Jarnagin WR, Roll FJ. Cell-specific expression of transforming growth factor-β in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 1995; 96: 447–55.
- 7 Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K, Gressner AM. Modulation of transforming growth factor β response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 2000; 31: 1094–106.
- 8 Kanzler S, Lohse AW, Keil A et al. TGF-β1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 1999; 276: G1059–68.
- 9 Sanderson N, Factor V, Nagy P et al. Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995; 92: 2572–6.
- 10 Varela-Rey M, Montiel-Duarte C, Oses-Prieto JA et al. P38 MAPK mediates the regulation of α1(I) procollagen mRNA levels by TNF-α and TGF-β in a cell line of rat hepatic stellate cells. FEBS Lett 2002; 528: 133–8.
- 11 Tahashi Y, Matsuzaki K, Date M et al. Differential regulation of TGF-β signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 2002; 35: 49–61.
- 12 Dooley S, Dolvoux B, Streckert M et al. Transforming growth factor β signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibrosis. FEBS Lett 2001; 502: 4–10.
- 13 Inagaki Y, Nemoto T, Nakao A et al. Interaction between GC box binding factors and Smad proteins modulates cell lineage-specific α2(I) collagen gene transcription. J Biol Chem 2001; 276: 16573–9.
- 14 Paradis V, Dargere D, Bonvoust F, Vidaud M, Segarini P, Bedossa P. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab Invest 2002; 82: 767–73.
- 15 Roulot D, Sevcsik AM, Coste T, Strosberg AD, Marullo S. Role of transforming growth factor β−type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats. Hepatology 1999; 29: 1730–8.
- 16 Wrana JL. Regulation of Smad activity. Cell 2000; 100: 189–92.
- 17 Miyazono K. TGF-β/Smad signaling and its involvement in tumor progression. Biol Pharm Bull 2000; 23: 1125–30.
- 18 Ten Dijke P, Goumans MJ, Itoh F, Itoh S. Regulation of cell proliferation by Smad proteins. J Cell Physiol 2002; 191: 1–16.
- 19 Attisano L, Wrana JL. Signal transduction by the TGF-β superfamily. Science 2002; 296: 1646–7.
- 20 Kloos DU, Choi C, Wingender E. The TGF-β-smad network: introducing bioinformatic tools. Trends Genet 2002; 18: 96–103.
- 21 Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGFβ signal transduction. J Cell Sci 2001; 114: 4359–69.
- 22 Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001; 34: 89–100.
- 23 Liu C, Gaca MD, Swenson ES, Vellucci VF, Reiss M, Wells RG. Smad 2 and 3 are differentially activated by transforming growth factor-β (TGF-β) in quiescent and activated hepatic stellate cells. J Biol Chem 2003; 278: 11721–8.
- 24 Souchelnytskyi S, Tamaki K, Engstrom U, Wernstedt C, Ten Dijke P, Heldin CH. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-β signaling. J Biol Chem 1997; 272: 28107–15.
- 25 De Caestecker MP, Hemmati P, Larisch-Bloch S, Ajmera R, Roberts AB, Lechleider RJ. Characterization of functional domains within Smad4/DPC4. J Biol Chem 1997; 272: 13690–6.
- 26 Imamura T, Takase M, Nishihara A et al. Smad6 inhibits signaling by the TGF-β superfamily. Nature 1997; 389: 622–6.
- 27 Hayashi H, Abdollah S, Qiu Y et al. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 1997; 89: 1165–73.
- 28 Nakao A, Afrakhte M, Moren A et al. Identification of Smad7, a TGFβ-inducible antagonist of TGFβ signaling. Nature 1997; 389: 631–5.
- 29 Dooley S, Hamzavi J, Breitkopf K et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003; 125: 178–91.
- 30 Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425–79.
- 31 Lin X, Liang M, Feng XH. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-β signaling. J Biol Chem 2000; 275: 36818–22.
- 32 Zuscik MJ, Rosier RN, Schwarz EM. Altered negative regulation of transforming growth factor β signaling in scleroderma: potential involvement of SMURF2 in disease. Arthritis Rheum 2003; 48: 1779–80.
- 33 Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci USA 2001; 98: 974–9.
- 34 Kavsak P, Rasmussen RK, Causing CG et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFβ receptor for degradation. Mol Cell 2000; 6: 1365–75.
- 35 Bonni S, Wang HR, Causing CG et al. TGF-β induces assembly of a Smad2–Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat Cell Biol 2001; 3: 587–95.
- 36 Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGFβ signaling by the SnoN oncoprotein. Science 1999; 286: 771–4.
- 37 Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor β signaling. Proc Natl Acad Sci USA 1999; 96: 12442–7.
- 38 Takiya S, Tagaya T, Takahashi K et al. Role of transforming growth factor beta 1 on hepatic regeneration and apoptosis in liver disease. J Clin Pathol 1995; 48: 1093–7.
- 39 Ichikawa T, Zhang YQ, Kogure K et al. Transforming growth factor β and activin tonically inhibit DNA synthesis in the rat liver. Hepatology 2001; 34: 918–25.
- 40 Togawa A, Yamamoto T, Susuki H et al. Ubiquitin-dependent degradation of Smad2 is increased in the glomeruli of rats with anti-thymocyte serum nephritis. Am J Pathol 2003; 163: 1645–52.
- 41 Fukasawa H, Yamamoto T, Togawa A et al. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA 2004; 101: 8687–92.
- 42 Fukuchi M, Fukai Y, Masuda N et al. High level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res 2002; 62: 7162–5.
- 43 Fukasawa H, Yamamoto T, Togawa A et al. Ubiquitin- dependent degradation of SnoN and Ski is increased in renal fibrosis induced by obstructive injury. Kidney Int 2006; 69: 1733–40.
- 44 Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf2-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 2004; 113: 253–64.
